Movement Alert｜INSILICO Falls 5.03% in Regular Trading, New Share Issuance Dilution Compounds Sector-Wide Selloff

Market Focus09-24

On September 24, INSILICO fell 5.03% in regular trading, trading at 55.85 HKD/share, with turnover of HKD 650 million, extending the prior session's decline.

On the news front, the company recently issued new shares, passively diluting Chairman Aleksandrs Zavoronkovs' stake from 8.02% to 7.99%, with his holding volume unchanged at approximately 46.757 million shares. The equity expansion raised market concerns over shareholder dilution. Meanwhile, the broader Life Sciences Tools and Services sector came under significant selling pressure, with GENSCRIPT BIO down 6.37%, XTALPI down 3.58%, WUXI BIO down 2.27%, WUXI XDC down 1.43%, and WUXI APPTEC down 1.35%, dragging on sentiment across the board.

It is worth noting that INSILICO had previously announced a collaboration with an AI lab valued at up to tens of millions of USD and saw its core drug Rentosertib enter Phase III trials. JPMorgan maintained an Overweight rating with a target price of 71 HKD, while Citi maintained a Buy rating with a target of 85 HKD.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1153230988?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-24 13:58","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1153230988","market":"us","top_or_hot":-1,"title":"Movement Alert｜INSILICO Falls 5.03% in Regular Trading, New Share Issuance Dilution Compounds Sector-Wide Selloff","media":"Market Focus","content":"<p><p>On September 24, INSILICO fell 5.03% in regular trading, trading at 55.85 HKD/share, with turnover of HKD 650 million, extending the prior session's decline.</p><p>On the news front, the company recently issued new shares, passively diluting Chairman Aleksandrs Zavoronkovs' stake from 8.02% to 7.99%, with his holding volume unchanged at approximately 46.757 million shares. The equity expansion raised market concerns over shareholder dilution. Meanwhile, the broader Life Sciences Tools and Services sector came under significant selling pressure, with GENSCRIPT BIO down 6.37%, XTALPI down 3.58%, WUXI BIO down 2.27%, WUXI XDC down 1.43%, and WUXI APPTEC down 1.35%, dragging on sentiment across the board.</p><p>It is worth noting that INSILICO had previously announced a collaboration with an AI lab valued at up to tens of millions of USD and saw its core drug Rentosertib enter Phase III trials. JPMorgan maintained an Overweight rating with a target price of 71 HKD, while Citi maintained a Buy rating with a target of 85 HKD.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜INSILICO Falls 5.03% in Regular Trading, New Share Issuance Dilution Compounds Sector-Wide Selloff</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜INSILICO Falls 5.03% in Regular Trading, New Share Issuance Dilution Compounds Sector-Wide Selloff\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-09-24 13:58</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On September 24, INSILICO fell 5.03% in regular trading, trading at 55.85 HKD/share, with turnover of HKD 650 million, extending the prior session's decline.</p><p>On the news front, the company recently issued new shares, passively diluting Chairman Aleksandrs Zavoronkovs' stake from 8.02% to 7.99%, with his holding volume unchanged at approximately 46.757 million shares. The equity expansion raised market concerns over shareholder dilution. Meanwhile, the broader Life Sciences Tools and Services sector came under significant selling pressure, with GENSCRIPT BIO down 6.37%, XTALPI down 3.58%, WUXI BIO down 2.27%, WUXI XDC down 1.43%, and WUXI APPTEC down 1.35%, dragging on sentiment across the board.</p><p>It is worth noting that INSILICO had previously announced a collaboration with an AI lab valued at up to tens of millions of USD and saw its core drug Rentosertib enter Phase III trials. JPMorgan maintained an Overweight rating with a target price of 71 HKD, while Citi maintained a Buy rating with a target of 85 HKD.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03696","symbol_name":"英矽智能","start_time":0,"source_url":"","article_id":"1153230988","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1153230988","pubTimestamp":1790229497,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On September 24, INSILICO fell 5.03% in regular trading, trading at 55.85 HKD/share, with turnover of HKD 650 million, extending the prior session's decline.On the news front, the company recently...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03696":"英矽智能"},"translate_title":"走势警报|INSILICO 常规交易中下跌 5.03%，新股发行稀释加剧全行业抛售","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03696":1},"content_text":"On September 24, INSILICO fell 5.03% in regular trading, trading at 55.85 HKD/share, with turnover of HKD 650 million, extending the prior session's decline.On the news front, the company recently issued new shares, passively diluting Chairman Aleksandrs Zavoronkovs' stake from 8.02% to 7.99%, with his holding volume unchanged at approximately 46.757 million shares. The equity expansion raised market concerns over shareholder dilution. Meanwhile, the broader Life Sciences Tools and Services sector came under significant selling pressure, with GENSCRIPT BIO down 6.37%, XTALPI down 3.58%, WUXI BIO down 2.27%, WUXI XDC down 1.43%, and WUXI APPTEC down 1.35%, dragging on sentiment across the board.It is worth noting that INSILICO had previously announced a collaboration with an AI lab valued at up to tens of millions of USD and saw its core drug Rentosertib enter Phase III trials. JPMorgan maintained an Overweight rating with a target price of 71 HKD, while Citi maintained a Buy rating with a target of 85 HKD.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"shareholding","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1153230988","isCrawlerRequest":true}